Abstract
Pancreatic cancer is a devastating malignancy with a median survival of less than one year. The exceedingly poor prognosis for metastatic pancreatic cancer patients remains a significant unmet medical need and is an opportunity for development of novel therapeutic approaches incorporating gene therapy strategies. Barriers exist preventing effective gene therapy including low transfection efficiency, poor tissue penetrance as well as non-specific delivery. However, one specific strategy using synthetic short interfering RNA fragments holds great potential and recently demonstrated successful systemic delivery using a transferrin (Tf)-targeted cyclodextrin-based polymer nanoparticle. Various nanoparticle formulations are currently being optimized for systemic gene therapy approaches. In this review, we highlight the rapidly progressing field of gene therapy strategies that have the potential to enhance the care of patients with devastating malignancies such as pancreatic cancer and focus on systemic delivery strategies to overcome remaining hurdles limiting widespread clinical applications.
Keywords: Gene therapy, Short interfering RNA fragment, Nanoparticle, Pancreatic cancer.
Current Cancer Therapy Reviews
Title:Optimizing Gene Silencing Strategies for Pancreatic Cancer
Volume: 9 Issue: 2
Author(s): Ernest Ramsay Camp, Katie Hurst, Cindy Wang, David J. Cole and Dennis K. Watson
Affiliation:
Keywords: Gene therapy, Short interfering RNA fragment, Nanoparticle, Pancreatic cancer.
Abstract: Pancreatic cancer is a devastating malignancy with a median survival of less than one year. The exceedingly poor prognosis for metastatic pancreatic cancer patients remains a significant unmet medical need and is an opportunity for development of novel therapeutic approaches incorporating gene therapy strategies. Barriers exist preventing effective gene therapy including low transfection efficiency, poor tissue penetrance as well as non-specific delivery. However, one specific strategy using synthetic short interfering RNA fragments holds great potential and recently demonstrated successful systemic delivery using a transferrin (Tf)-targeted cyclodextrin-based polymer nanoparticle. Various nanoparticle formulations are currently being optimized for systemic gene therapy approaches. In this review, we highlight the rapidly progressing field of gene therapy strategies that have the potential to enhance the care of patients with devastating malignancies such as pancreatic cancer and focus on systemic delivery strategies to overcome remaining hurdles limiting widespread clinical applications.
Export Options
About this article
Cite this article as:
Camp Ramsay Ernest, Hurst Katie, Wang Cindy, Cole David J. and Watson K. Dennis, Optimizing Gene Silencing Strategies for Pancreatic Cancer, Current Cancer Therapy Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573394711309020004
DOI https://dx.doi.org/10.2174/1573394711309020004 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science Investigation on the Effects of Antimicrobial imidazo[2,1-b]thiazole Derivatives on the Genitourinary Microflora
Medicinal Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Meet Our Editorial Board Member
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Overview of Systems Biology and Omics Technologies
Current Medicinal Chemistry Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry